​

Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

ForecastOwnershipFinancialsChartTranscripts
Amylyx Pharmaceuticals by TradingView

Previous Close

$13.99

52W Range

$3.11 - $17.49

50D Avg

$14.10

200D Avg

$11.45

Market Cap

$1.20B

Avg Vol (3M)

$1.43M

Beta

-0.30

Div Yield

-

AMLX Company Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

123

IPO Date

Jan 07, 2022

Website

AMLX Performance

AMLX Financial Summary

Dec 25Dec 24Dec 23
Revenue-$87.37M$380.79M
Operating Income$-153.29M$-314.73M$38.80M
Net Income$-144.74M$-301.74M$49.27M
EBITDA$-144.16M$-290.98M$39.89M
Basic EPS$-1.53$-4.43$0.73
Diluted EPS$-1.53$-4.43$0.70

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 03, 26 | 8:00 AM
Q3 25Nov 06, 25 | 8:00 AM
Q2 25Aug 07, 25 | 8:00 AM

Peer Comparison

TickerCompany
IMTXImmatics N.V.
ATAIAtai Beckley N.V
RLAYRelay Therapeutics, Inc.
NKTRNektar Therapeutics
CVACCureVac N.V.
SANASana Biotechnology, Inc.
SNDXSyndax Pharmaceuticals, Inc.
ORICORIC Pharmaceuticals, Inc.
PGENPrecigen, Inc.
INBXInhibrx Biosciences, Inc.